Streetwise Reports' Article Archives — September 2023 back to current month (13)
This telehealth company has signed a contract with a physician network to add as many as 100,000 patients to its platform. Find out why the CEO says it is in a period of rapid growth.
Biopharma Co. Adds CTO to Team (09/21/2023)
This newest member brings with him extensive experience in protein development and manufacturing, noted an Oppenheimer report.
This product candidate presents a compelling approach to treating post-surgery chronic rhinosinusitis patients, noted an H.C. Wainwright & Co. report.
Biotech Co. Makes Strides on Three Fronts (09/19/2023)
This Canadian firm sold assets, launched an equity raise and filed a clinical trial application for its lead psychedelic-assisted psychotherapy program, noted a Stifel report.
This telehealth company has signed a new contract for its remote patient monitoring platform to be used by a leading healthcare company with dozens of locations in eight states.
This telehealth company is expanding its platform to cover remote monitoring for pediatric patients with diabetes and other eligible conditions. Find out why one analyst says this company's stock is gathering momentum.
Co. Reaches Major Milestone With Novel Drug (09/07/2023)
The biopharma initiated enrollment of a targeted 420 patients for one of its Phase 3 clinical trials evaluating its new cardiac myosin inhibitor, noted an H.C. Wainwright & Co. report.
Cryoablation System Gets Approved in Brazil (09/07/2023)
The product developer expects to generate US$6.6 million in sales of this medical device in Brazil over the next five years, noted an H.C. Wainwright & Co. report.
Awakn Life Sciences has applied for Phase 3 of clinical trials after the success of Phase 2. Read on to see what this company plans for its flagship new drug.
McAlinden Research shares a deep dive into a market driver with alpha-generating potential.
This telehealth company has signed a new contract with a Texas respiratory clinic that is expected to add 10,000 new patients to its iUGO platform by mid-2024. Read to see why one analyst believes this stock is a Buy.
The company behind the vaccine plans to use the safety data to support approvals in the U.S., European Union and Brazil, noted an H.C. Wainwright & Co. report.
Based on these positive Phase 1 trial results in actinic keratosis, the biopharma developer will seek label expansion in the U.S., noted a ROTH Capital Partners report.